Crosswave Management
Seed and startup-scale investor focused on healthcare. Also provides cross-border partnering services.
Dr. Charles Hsu
Managing PartnerCRUise
CRUise is the largest SMO Network in MEA region, we are aiming to have a network of clinical research units and Key Opinion Leaders interested in Clinical Research. CRUise will ensure the quality of research by having a network with unified international standards.
Hadil Noureddine
Project ManagerCureMeta
CureMeta is a therapeutic oncology biotech with the mission to develop therapeutic antibodies to novel cancer targets that are present in aggressive cancers and to develop new powerful cancer drugs to provide meaningful treatments and cures for patients with metastatic cancer.
We are seeking partners to out-license our lead therapeutic: CM-09, a first in class Antibody-Drug-Conjuate for gastric cancers.
Dr. MIke Schopperle
CSOCurika
CURIKA, our health based app aims to revolutionize healthcare delivery through mobile/web based platform. We connect Patients, Doctors, Nurses, and Diagnostic Centres across geographies, technology and workflow boundaries. We provide online medical equipment (Rent / Purchase), Nursing Staff, Physiotherapist & Ayurvedic Therapist at door step of end user.
Mr. Anil Nair
CEOCytiva
Cytiva is a global provider of technologies and services that help advance and accelerate the development and manufacture of therapeutics. Previously GE Healthcare Life Sciences, Cytiva’s diverse portfolio includes well-recognized brands such as ÄKTA, Amersham, Biacore, FlexFactory, HyClone, MabSelect, Sefia, Whatman, Xcellerex and Xuri. Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the delivery of transformative medicines to patients. Visit cytiva.com for more information
Dr. Daniel Floyd
Search and Evaluation Director, AsiaCytomX Therapeutics
Clinical stage bio pharmaceutical company with Probody platform to treat cancer.
Simon He
Director of FinanceCytovance Biologics
Cytovance® Biologics is a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO) that excels in the rapid and cost-effective development and manufacture of large molecule APIs from both mammalian cell culture and microbial fermentation such as monoclonal antibodies, fragment antibodies, bispecifics, enzymes, fusion proteins, vaccines and other biological products including plasmid DNA and cell-based therapeutics. In addition to our clinical and commercial cGMP API manufacturing services, Cytovance offers well integrated development services supporting the entire product lifecycle including cell line development, cell banking, microbial strain development, process and analytical development, and process characterization. A centralized, responsive program management team coordinates all critical CMC activities for each client program around raw materials management, QC testing, ICH stability studies, and regulatory support. Our 140,000 sq. ft. state-of-the-art facilities in Oklahoma City are designed to meet U.S., EU, and other global regulatory standards.